On September 8, 2026, GRI Bio announced new translational biomarker data from its Phase 2a study of GRI-0621 (oral tazarotene) in patients with idiopathic pulmonary fibrosis. The data demonstrated a repair phenotype characterized by immune re-balancing, myofibroblast inhibition, and net basement membrane repair across four independent measurement modalities. Placebo-adjusted forced vital capacity increased by 99 mL overall and 139 mL in patients on background standard-of-care therapy. Treatment-related cough was 0% versus 25% for placebo, and diarrhea occurred in 17% of treated patients compared to 33%. The company plans to advance GRI-0621 into a longer-duration study. GRI Bio is a clinical-stage biopharmaceutical company developing therapies for inflammatory, fibrotic, and autoimmune diseases.

GRI Bio, Inc. announced on June 18, 2026, that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to GRI-0621 for treating idiopathic pulmonary fibrosis. GRI Bio, Inc. is a biotechnology company focused on developing therapeutic solutions for rare diseases.